Table 1.
Total number of evaluable patients | 30 | |
---|---|---|
Age, median (range) | 63(44–78) | |
Characteristic | N | % |
Gender | ||
Male | 18 | 60 |
Female | 12 | 40 |
Ethnicity | ||
Caucasian | 23 | 77 |
African American | 6 | 20 |
Hispanic | 1 | 3 |
Clinical stage | ||
IB | 2 | 7 |
IIA | 1 | 3 |
IIB | 11 | 37 |
IIIA | 13 | 43 |
IIIB | 3 | 10 |
Histology | ||
Adenocarcinoma | 16 | 53 |
Squamous cell carcinoma | 7 | 23 |
Other | 7 | 23 |
Neoadjuvant chemotherapy | ||
Cisplatin | 11 | 37 |
+ Taxane | 9 | |
+ Other | 2 | |
<3 cycles | 5 | |
≥3 cycles | 6 | |
Carboplatin | 19 | 63 |
+ Taxane | 17 | |
+ Other | 2 | |
<3 cycles | 8 | |
≥3 cycles | 11 | |
Smoking status | ||
Current smoker | 10 | 33 |
Former smoker | 10 | 33 |
Never smoker | 5 | 17 |
Undocumented | 5 | 17 |
Tumor response by RECIST | ||
Stable disease | 22 | 73 |
Partial response | 8 | 27 |
Tobacco pack years | 32 (0–145) | |
Time lapse from last chemotherapy (days) | 37 (22–71) |
Abbreviations: RECIST= Response Evaluation Criteria in Solid Tumors